Predictors of low cardiac output in decompensated severe heart failure
- PMID: 21484040
- PMCID: PMC3059880
- DOI: 10.1590/s1807-59322011000200010
Predictors of low cardiac output in decompensated severe heart failure
Abstract
Objective: To identify predictors of low cardiac output and mortality in decompensated heart failure.
Introduction: Introduction: Patients with decompensated heart failure have a high mortality rate, especially those patients with low cardiac output. However, this clinical presentation is uncommon, and its management is controversial.
Methods: We studied a cohort of 452 patients hospitalized with decompensated heart failure with an ejection fraction of <0.45. Patients underwent clinical-hemodynamic assessment and Chagas disease immunoenzymatic assay. Low cardiac output was defined according to L and C clinical-hemodynamic profiles. Multivariate analyses assessed clinical outcomes. P<0.05 was considered significant.
Results: The mean age was 60.1 years; 245 (54.2%) patients were >60 years, and 64.6% were men. Low cardiac output was present in 281 (63%) patients on admission. Chagas disease was the cause of heart failure in 92 (20.4%) patients who had higher B type natriuretic peptide levels (1,978.38 vs. 1,697.64 pg/mL; P = 0.015). Predictors of low cardiac output were Chagas disease (RR: 3.655, P<0.001), lower ejection fraction (RR: 2.414, P<0.001), hyponatremia (RR: 1.618, P = 0.036), and renal dysfunction (RR: 1.916, P = 0.007). Elderly patients were inversely associated with low cardiac output (RR: 0.436, P = 0.001). Predictors of mortality were Chagas disease (RR: 2.286, P<0.001), ischemic etiology (RR: 1.449, P = 0.035), and low cardiac output (RR: 1.419, P = 0.047).
Conclusions: In severe decompensated heart failure, predictors of low cardiac output are Chagas disease, lower ejection fraction, hyponatremia, and renal dysfunction. Additionally, Chagas disease patients have higher B type natriuretic peptide levels and a worse prognosis independent of lower ejection fraction.
Figures
Comment in
-
Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers.Clinics (Sao Paulo). 2011;66(7):1275-6. doi: 10.1590/s1807-59322011000700025. Clinics (Sao Paulo). 2011. PMID: 21876986 Free PMC article. No abstract available.
References
-
- Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, et al. OPTIMIZE‐HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE‐HF registry. Eur Heart J. 2007;28:980–8. - DOI - PubMed
-
- Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, et al. In‐hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am Coll Cardiol. 2005;46:57–64. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
